Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.

Permana H, Yanto TA, Hariyanto TI

Diabetes & metabolic syndrome14 Oct 2022Cited by 29 (Europe PMC)

PMID36274410DOI10.1016/j.dsx.2022.102640PepBankPUB-36274410

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide lowered HbA1c versus placebo by 1.50% (5 mg) to 1.80% (15 mg), in a dose-dependent way.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide lowered long-term blood sugar (HbA1c) more than placebo, with larger doses doing more.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Measurements
HbA1c reduction vs placebo (5 mg to 15 mg)
1.5 to 1.8%
tirzepatide vs placebo
Source sentences
Summary
Our pooled analysis revealed the dose-dependent superiority of tirzepatide in reducing HbA_1c, ranging from -1.50% with 5 mg to -1.80% with 15 mg when compared with placebo
2 context sentences(design, population, supporting numbers)
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441001
02HumanSystematic reviewEfficacy outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide lowered HbA1c versus a GLP-1 receptor agonist by 0.61% (5 mg) to 0.95% (15 mg).
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide lowered long-term blood sugar (HbA1c) more than a GLP-1 receptor agonist drug.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction vs GLP-1 receptor agonist
Study
n: not reported in source
Comparator
GLP-1 receptor agonist (drugs not named)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Measurements
HbA1c reduction vs GLP-1 receptor agonist (5 mg to 15 mg)
0.61 to 0.95%
tirzepatide vs GLP-1 RA
Source sentences
Summary
-0.61% with 5 mg to -0.95% with 15 mg when compared with GLP-1 receptor agonist
3 context sentences(design, population, supporting numbers)
Summary · context
Our pooled analysis revealed the dose-dependent superiority of tirzepatide in reducing HbA_1c
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441002
03HumanSystematic reviewEfficacy outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide lowered HbA1c versus basal insulin by 0.70% (5 mg) to 1.09% (15 mg).
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide lowered long-term blood sugar (HbA1c) more than basal insulin.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction vs basal insulin
Study
n: not reported in source
Comparator
Basal insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Measurements
HbA1c reduction vs basal insulin (5 mg to 15 mg)
0.7 to 1.09%
tirzepatide vs basal insulin
Source sentences
Summary
-0.70% with 5 mg to 1.09% with 15 mg when compared with basal insulin
3 context sentences(design, population, supporting numbers)
Summary · context
Our pooled analysis revealed the dose-dependent superiority of tirzepatide in reducing HbA_1c
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441003
04HumanSystematic reviewEfficacy outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide reduced bodyweight more than all comparators, in a dose-dependent way.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide reduced body weight more than comparator treatments, with larger doses doing more.
Peptide
Tirzepatide
Outcome
DecreaseBodyweight reduction vs all comparators
Study
n: not reported in source
Comparator
All comparators (placebo or other glucose lowering agents)
Outcome group
Body weight · Metabolic and weight
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Source sentences
Summary
The dose-dependent superiority of tirzepatide was also seen in the bodyweight reduction effect with all comparators.
2 context sentences(design, population, supporting numbers)
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441004
05HumanSystematic reviewSafety outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide was not accompanied by increased odds of hypoglycemia.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide did not raise the odds of low blood sugar.
Peptide
Tirzepatide
Outcome
No significant changeHypoglycemia odds
Study
n: not reported in source
Comparator
Placebo or other glucose lowering agents
Outcome group
Adverse events · Metabolic and weight
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Source sentences
Summary
These superiorities were not accompanied by increased odds of hypoglycemia
2 context sentences(design, population, supporting numbers)
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441005
06HumanSystematic reviewSafety outcome
In a pooled analysis of nine trials in adults with type 2 diabetes, tirzepatide increased the incidence of gastrointestinal adverse events.
In plain wordsIn pooled trials of adults with type 2 diabetes, stomach and gut side effects were more common with tirzepatide.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo or other glucose lowering agents
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg once weeklyAs given in this study (human).
Source sentences
Summary
there is an increase in gastrointestinal adverse events incidence
2 context sentences(design, population, supporting numbers)
Summary · context
We collected all clinical trials that compare tirzepatide 5, 10, or 15 mg once-weekly with placebo or other glucose lowering agents in adult patients with T2D.
Summary · context
Nine clinical trials were included.
Report a problemFND-3627441006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 12:39 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.